Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Andres Chang, Adam Pelletier, Donald J McGuire, Maria Tsagiopoulou, Maria Karipidou, Amy Ayers, Alyssa Leal, Michael Churnetski, Colin B O'Leary, Jeffrey M. Switchenko, Carl Davis, David A. Frank, Jean L. Koff, Jonathon B Cohen, Rafick-Pierre Sekaly, Kostas Stamatopoulos, Christopher R. Flowers, Rafi Ahmed

Blood (2024) 144 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2024-200302

Published: 2024

Journal Articles

Use of an Integrated Functional Quantitation of Modulation of Transcriptional Pathways (IFQ) Assay in Untreated Mantle Cell Lymphoma Patients

Drew Gerber, Melanie Lopez-McDonald, Weiyuan Wang, Jean L. Koff, Michael Churnetski, Colin B O'Leary, Jonathon B. Cohen, David A. Frank

Blood (2023) 142 (Supplement 1): 6103.

https://doi.org/10.1182/blood-2023-190441

Published: 2023

Journal Articles

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Bianca L Rivera, Shanisha Gordon, Srinivas Aluri, Yang Shi, Samarpana Chakraborty, Gaurav S Choudhary, Lauren C Shapiro, Kith Pradhan, David A. Frank, Sergei B. Koralov, Amit Verma, Aditi Shastri

Blood (2021) 138 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2021-151691

Published: 2021

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia

Jennifer R. Brown, MD PhD, Sarah R. Walker, PhD, Lisa N. Heppler, Svitlana Tyekucheva, Erik Nelson, PhD, Josephine L. Klitgaard, MSc, PhD, Maria Nicolais, MD, Yasmin Kroll, Michael Xiang, MD PhD, Jennifer E. Yeh, MD PhD, Mousumi Chaudhury, Zachary T. Giaccone, Stacey Fernandes, Jeffrey G. Supko, PhD, Catherine J. Wu, MD, David A. Frank, MD PhD

Blood (2018) 132 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2018-99-118921

Published: 2018

Journal Articles

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Jeffrey Nemeth, PhD, Shruti Bhatt, PhD, Sarah R Walker, Natalie I Voeks, William Lento, PhD, Ricardo M. Attar, Ilene Galinsky, MSN, ANPc, David A Frank, MD PhD, Martha Wadleigh, MD, Anthony Letai, MD PhD, David P. Steensma, MD, David M. Weinstock, MD, Daniel J. DeAngelo, MD PhD, David M. Dorfman, MD PhD, Richard M. Stone, MD, James D Griffin, MD

Blood (2016) 128 (22): 1681.

https://doi.org/10.1182/blood.V128.22.1681.1681

Published: 2016

Journal Articles

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Blood (2016) 128 (14): 1845–1853.

https://doi.org/10.1182/blood-2015-07-660506

Published: 2016

Includes: Supplemental data

Journal Articles

Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine

Aditi Shastri, MD, Carolina Schinke, MD, Asya Varshavsky Yanovsky, MD PhD, Tushar D. Bhagat, PhD, Orsolya Giricz, Laura Barreyro, M.Sc., Jacqueline Boultwood, PhD, Andrea Pellagati, Yiting Yu, PhD, Jennifer R. Brown, MD PhD, David A. Frank, MD PhD, Bhaskar Das, PhD, Suman Kambhampati, MD, Britta Will, PhD, Ulrich Steidl, MDPhD, Amit Verma, MD

Blood (2014) 124 (21): 3602.

https://doi.org/10.1182/blood.V124.21.3602.3602

Published: 2014

Journal Articles

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Erik A. Nelson, Sarah R. Walker, Ellen Weisberg, Michal Bar-Natan, Rosemary Barrett, Laurie B. Gashin, Shariya Terrell, Josephine L. Klitgaard, Loredana Santo, Martha R. Addorio, Benjamin L. Ebert, James D. Griffin, David A. Frank

Blood (2011) 117 (12): 3421–3429.

https://doi.org/10.1182/blood-2009-11-255232

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Michal Bar-Natan, M.D, Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Rosemary Barrett, B.S., David A. Frank, MD, PhD

Blood (2009) 114 (22): 1905.

https://doi.org/10.1182/blood.V114.22.1905.1905

Published: 2009

Journal Articles

STAT6 in PMBL: pathogenic or passenger?

David A. Frank

Blood (2009) 114 (6): 1133–1134.

https://doi.org/10.1182/blood-2009-05-221770

Published: 2009

Journal Articles

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

Erik A. Nelson, Sarah R. Walker, Alicia Kepich, Laurie B. Gashin, Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Kenneth C. Anderson, David A. Frank

Blood (2008) 112 (13): 5095–5102.

https://doi.org/10.1182/blood-2007-12-129718

Published: 2008

Includes: Supplemental data

Journal Articles

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Alicia Kepich, B.S., Shariya Terrell, B.S., Laurie Gashin, B.S., David A. Frank, M.D., Ph.D.

Blood (2007) 110 (11): 2953.

https://doi.org/10.1182/blood.V110.11.2953.2953

Published: 2007

Journal Articles

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

Erik A. Nelson, PhD, Teru Hideshima, M.D. Ph.D, Laurie Gashin, Sarah R. Walker, B.S., Rebecca A. Lynch, B.S., Dharminder Chauhan, Ph.D., Kenneth C. Anderson, M.D., David A. Frank, M.D.,Ph.D.

Blood (2006) 108 (11): 3450.

https://doi.org/10.1182/blood.V108.11.3450.3450

Published: 2006

Journal Articles

IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

Emmanuel Zorn, Erik A. Nelson, Mehrdad Mohseni, Fabrice Porcheray, Haesook Kim, Despina Litsa, Roberto Bellucci, Elke Raderschall, Christine Canning, Robert J. Soiffer, David A. Frank, Jerome Ritz

Blood (2006) 108 (5): 1571–1579.

https://doi.org/10.1182/blood-2006-02-004747

Published: 2006

Journal Articles

The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells

Traci E. Battle, Jack Arbiser, David A. Frank

Blood (2005) 106 (2): 690–697.

https://doi.org/10.1182/blood-2004-11-4273

Published: 2005

Journal Articles

The Natural Product Honokiol Induces Caspase-Dependent Apoptosis in Chronic Lymphocytic Leukmemia (CLL) Cells.

Traci E. Battle, Ph.D., Jack Arbiser, M.D., Ph.D., David A. Frank, M.D., Ph.D.

Blood (2004) 104 (11): 4777.

https://doi.org/10.1182/blood.V104.11.4777.4777

Published: 2004

Journal Articles

Molecular Events Underlying the Induced Differentiation of CLL Cells Are Recapitulated in Cess B Cells.

Traci E. Battle, Ph.D., David A. Frank, M.D., Ph.D.

Blood (2004) 104 (11): 4778.

https://doi.org/10.1182/blood.V104.11.4778.4778

Published: 2004

Journal Articles

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1

Traci E. Battle, David A. Frank

Blood (2003) 102 (8): 3016–3024.

https://doi.org/10.1182/blood-2002-09-2972

Published: 2003

NARROW

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Use of an Integrated Functional Quantitation of Modulation of Transcriptional Pathways (IFQ) Assay in Untreated Mantle Cell Lymphoma Patients

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

STAT6 in PMBL: pathogenic or passenger?

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma.

IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells

The Natural Product Honokiol Induces Caspase-Dependent Apoptosis in Chronic Lymphocytic Leukmemia (CLL) Cells.

Molecular Events Underlying the Induced Differentiation of CLL Cells Are Recapitulated in Cess B Cells.

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only